uniQure (QURE)

Executive Summary

uniQure is a Dutch gene therapy pioneer with a proprietary AAV5 platform and a legacy as the first company to gain Western approval for a gene therapy (Glybera). The company is advancing a pipeline focused on severe genetic and neurodegenerative disorders, including lead programs AMT-130 for Huntington's disease (Phase 1/2), AMT-162 for ALS (Phase 1/2), and AMT-191 for Fabry disease (Phase 1/2). Despite a rich history and a strong platform, uniQure's valuation (~$1.5B) reflects its early-stage pipeline and commercial risk. The company's ability to demonstrate clinical proof-of-concept and secure regulatory milestones in the near term will be critical to its growth trajectory.

Upcoming Catalysts (preview)

• H2 2026AMT-130 Huntington's Disease Phase 1/2 Data Update60% success
• H1 2027AMT-191 Fabry Disease Initial Phase 1/2 Safety and Efficacy Results50% success
• H1 2026Potential Partnership or Milestone Payment for AMT-162 (ALS)30% success